New cancer biomarkers may be provided by the implementation of the easily, into clinical practice, introducible sPD-L1 and sPD-1, as these have demonstrated significance in tumor prognosis and possible systemic effect for cancer proliferation. This evidence concerns the gene SPDL1 and neoplasm.